



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – **New Programs:** Temozolomide and Radiation for Elderly Patients with Newly Diagnosed Glioma, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma, Adjuvant Capecitabine and Gemcitabine for Pancreatic Adenocarcinoma, Bevacizumab and Temozolomide for Advanced Solitary Fibrous Tumours and Hemangiopericytoma
- **Benefit Drug List** – **New:** CNELTZRT, GIPAJGCAP, UMYLDF; USATEMBEV; **Revised:** HNLACETRTR, HNNAVCAP, HNNAVPC, LKATOATRA, LKATOP, LKATOR
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts:** **New:** CNELTZRT, GIPAJGCAP, UMYLDF, USATEMBEV ; **Revised:** CNB, CNBEV, CNCAB, CNCARV, CNCCNU, CNPROC, CNQUIN, CNTAM, GIAVCETIR, GIAVPANI, GIGAJCPRT, UGIYTT, GOBEP, HNLACETRTR, HNNAVCAP, HNNAVPC, LKATOATRA, LKATOP, LKATOR, ULKMDSA, ULKMFRUX, UGUAVNIV, ULUAVNIV, USMAVNIV, USMAVPEM, USMAVVEM
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

Effective 1 April 2017, the BCCA Provincial Systemic Therapy Program has approved the following programs.

Neuro-Oncology:

Concurrent and Adjuvant Temozolomide and Radiation Therapy for Elderly Patients with Newly Diagnosed Glioma (CNELTZRT) – Approval of this new program is based on one phase III trial showing chemoradiotherapy was superior to radiotherapy alone in median overall survival (7.6 vs. 9.3 mos) and 2-year survival rate (10.4% vs. 2.8%). Toxicity was modest with about 10% increase in grade 3 and 4 neutropenia and thrombocytopenia.¹

Multiple Myeloma:

Lenalidomide with Low-Dose Dexamethasone for Newly Diagnosed Multiple Myeloma (UMYLDF) – A new treatment option of lenalidomide plus dexamethasone (LENDEX) is now approved for patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplant. Currently such patients can be treated with either melphalan and prednisone (MP) plus bortezomib (MYMPBOR) or plus thalidomide (UMYMPT). MP-bortezomib is preferred, and MP-thalidomide is offered to patients who live at some distance and would otherwise need to travel far for the frequent bortezomib dosing. Approval of the new combination of lenalidomide and dexamethasone (LENDEX) is based on a phase III trial showing increased

progression free survival (25.5 vs. 21.2 mos) compared to MP-thalidomide.² The LENDEX regimen will replace MP-thalidomide and be an alternative to MP-bortezomib. Access to this new program will require a BCCA Compassionate Access Program approval.

Gastrointestinal:

Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Using Capecitabine and Gemcitabine (GIPAJGAP) – Currently adjuvant gemcitabine is the standard treatment for resected pancreatic adenocarcinoma. Approval of the new treatment program was based on phase III trial where the combination demonstrated improved overall survival compared to gemcitabine alone (28 mos vs. 25.5 mos), with similar toxicities.³ It is expected that the adjuvant combination regimen will be used in most patients with resected pancreatic adenocarcinoma.

Sarcoma:

Bevacizumab and Temozolomide for Advanced Solitary Fibrous Tumours and Hemangiopericytoma (USATEMBEV) – Patients with advanced solitary fibrous tumours (SFT) and hemangiopericytoma that are no longer amenable to surgical resection are now eligible to receive this treatment through the BCCA Compassionate Access Program (CAP). Advanced SFT and hemangiopericytoma are rare diseases for which there is no current standard of care. In a small retrospective study, bevacizumab with temozolomide demonstrated a partial response rate of 14% and a stable disease rate of 86% as per the RECIST criteria.⁴ The estimated median progression-free survival was 10.8 months. Treatment was generally well tolerated, with myelosuppression being the most commonly reported toxicity.

References:

1. Perry, JR, et al. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma. *J Clin Oncol* 2016;34: LBA2 (Abstr).
2. Benboubker L, et al. Lenalidomide and dexamethasone in transplant ineligible patient with myeloma. *N Engl J Med* 2014; 371 (10):906-17.
3. Neoptolemos, JP et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicenter, open-label, randomized, phase 3 trial. *Lancet* 2017;389:1011–24.
4. Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. *Cancer* 2011;117:4939-4947.

BENEFIT DRUG LIST

NEW PROGRAMS

Effective 1 April 2017, the following BCCA treatment programs have been added to the BCCA [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy	CNELTZRT	Class I
Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Using Capecitabine and Gemcitabine	GIPAJGCAP	Class I
Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant Using Lenalidomide with Low-dose Dexamethasone	UMYLDF	Restricted
Therapy for Advanced Solitary Fibrous Tumours and Hemangiopericytoma Using Temozolomide and Bevacizumab	USATEMBEV	Restricted

REVISED PROGRAMS

Effective 1 April 2017, the benefit status of the following BCCA treatment programs have been changed from Restricted to Class I on the BCCA [Benefit Drug List](#):

Protocol Title	Protocol Code
Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine	CNBEV
Combined Cetuximab and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck	HNLACETRT
Treatment of Recurrent or Metastatic Nasopharyngeal Cancer With Capecitabine	HNNAVCAP
Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma with CARBOplatin and PACLitaxel	HNNAVPC
First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin	LKATOATRA
First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin and DAUNOrubicin	LKATOP
Induction and Consolidation Therapy of Relapsed Acute Promyelocytic Leukemia Using Arsenic Trioxide	LKATOR

DELETED PROGRAMS

Effective 1 April 2017, the following BCCA treatment program has been deleted the BCCA [Benefit Drug List](#):

Protocol Title	Protocol Code
Treatment of Multiple Myeloma Using Melphalan, predniSONE and Thalidomide	UMYMPT

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BCCA Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)				
CODE	Protocol	PPPO	Patient Handout	Protocol Title
CNELTZRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy
GIPAJGCAP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Using Capecitabine and Gemcitabine
UMYLDF	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant Using Lenalidomide with Low-dose Dexamethasone
USATEMBEV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Therapy for Advanced Solitary Fibrous Tumours and Hemangiopericytoma Using Temozolomide and Bevacizumab

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title	
CNB	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Test and administration clarified</i>	Suppressive Therapy for Pituitary Adenomas using Bromocriptine
CNBEV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>CAP requirement deleted, dosing of lomustine and etoposide clarified</i>	Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine
CNCAB	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Test and administration clarified</i>	Suppressive Therapy for Pituitary Adenomas using Cabergoline
CNCARV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted with various clarifications</i>	CARBOplatin and Etoposide in the Treatment of Recurrent Ependymoma and Oligodendroglioma
CNCCNU	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted with various clarifications</i>	Lomustine (CCNU) for Treatment of Recurrent Malignant Brain Tumours
CNPROC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted with various clarifications</i>	Standard Procarbazine for Second-line Treatment of Recurrent Brain Tumour
CNQUIN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Test and administration clarified</i>	Suppressive Therapy for Pituitary Adenomas using Quinagolide
CNTAM	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Reformatted with various clarifications</i>	Tamoxifen For Patients With Recurrent Brain Tumours Which Are Resistant To First Line Chemotherapy
GIAVCETIR	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Magnesium infusion time revised</i>	Third Line Treatment of Metastatic Colorectal Cancer Using Cetuximab in Combination with Irinotecan
GIAVPANI	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Magnesium infusion time revised</i>	Palliative Third Line Treatment of Metastatic Colorectal Cancer Using Panitumumab
GIGAJCPR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Eligibility, Exclusions, addition of electrolytes, dose modifications</i>	Adjuvant Chemotherapy of Gastric Cancer patients with Completely Resected Gastric Cancer using CISplatin and Capecitabine and Radiation Therapy
UGIYTT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Yttrium-90 for Transarterial Radioembolisation (TARE)
GOBEP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Timing of prehydration clarified, filter size specified</i>	Therapy of Non-Dysgerminomatous Ovarian Germ Cell Cancer Using Bleomycin, Etoposide, and CISplatin
GOSMCCRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Hydration solutions changed to NS; electrolytes added to Tests</i>	Treatment of Small Cell or Neuroendocrine Carcinoma of Gynecologic System Origin using PACLitaxel, CISplatin, Etoposide and CARBOplatin with Radiation

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title	
UGUAVNIV	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Tests and treatment duration clarified, minor typo corrected</i>	Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Nivolumab
HNLACETRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>CAP requirement deleted, magnesium infusion time revised</i>	Combined Cetuximab and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
HNNVAVCAP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>CAP requirement deleted</i>	Treatment of Recurrent or Metastatic Nasopharyngeal Cancer With Capecitabine
HNNVAVPC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>CAP requirement deleted</i>	Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma with CARBOplatin and PACLitaxel
LKATOATRA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>CAP requirement deleted</i>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin
LKATOP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>CAP requirement deleted</i>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin and DAUNOrubicin
LKATOR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>CAP requirement deleted</i>	Induction and Consolidation Therapy of Relapsed Acute Promyelocytic Leukemia Using Arsenic Trioxide
ULKMDSA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Treatment duration updated</i>	Therapy of Myelodysplastic Syndrome using azaCITIDine
ULKMFRUX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Treatment duration updated</i>	Treatment of Symptomatic Myelofibrosis with Ruxolitinib
ULUAVNIV	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Tests and treatment duration clarified, minor typo corrected</i>	Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab
USMAVNIV	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Tests, treatment duration and toxicities management clarified</i>	Treatment of Unresectable or Metastatic Melanoma Using Nivolumab
USMAVPEM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab
USMAVVEM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Cautions updated</i>	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using vemURAFenib

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	WWW.BCCANCER.BC.CA
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-Printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Mario de Lemos, PharmD, MSc (Oncol) (Acting Editor)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Lorraine Leitz, MLS
 Ava Hatcher, RN, BN CONc
 Rob Watt, BSc(Pharm)